Table 1:

Clinical and demographic data

Patient No.	Sex	Age (yr)	Clinical Phenotype	EDSS	Disease Duration (yr)	Disease-Modifying Treatment
1	Female	60	RR	1.5	11	Dimethyl fumarate
2	Female	66	Progressive	7	28	None
3	Male	56	Progressive	6	24	None
4	Male	47	RR	1.5	16	Daclizumab
5	Female	43	RR	2	43	None
6	Female	64	RR	1.5	9	None
7	Female	55	RR	1.5	2	Interferon β-1a
8	Male	36	RR	1	7	Glatiramer acetate
9	Male	61	Progressive	6.5	40	None
10	Female	51	Progressive	6.5	24	None
11	Female	35	RR	1	4	Dimethyl fumarate
12	Female	36	RR	2.5	18	Glatiramer acetate
13	Male	38	RR	0	1	None
14	Female	28	RR	1.5	1	None
15	Female	33	RR	2	1	None
16	Female	42	RR	2.5	10	Mycophenolate mofetil
17	Female	25	RR	2	1	Glatiramer acetate
18	Female	30	RR	1.5	8	None
19	Female	36	RR	1.5	9	Dimethyl fumarate
20	Female	71	RR	1	15	None